Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Carmen Campbell

Rheumatology Madison, WI Medical Doctor

NPI 1124252887 CMS profile 1395118

451 Junction Rd, Madison, WI 53717

Open in the dashboard

General payments

$4,973

270 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Carmen Campbell of Madison, WI is reported in the CMS Open Payments database as having received $4,973 across 270 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $249 17
2022 General $1,153 47
2021 General $1,101 62
2020 General $677 40
2019 General $1,793 104

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carmen Campbell
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Carmen Campbell were reported at $0. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Carmen Campbell Rheumatology median Middle half National median
2019 $1,793 $744 $153–$2,687 $163
2020 $677 $462 $98–$2,027 $114
2021 $1,101 $531 $101–$2,153 $132
2022 $1,153 $627 $125–$2,303 $149
2023 $249 $741 $145–$2,524 $160
2024 $0 $830 $166–$2,660 $164
2025 $0 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AbbVie, Inc. $1,983 88 payments
  2. Novartis Pharmaceuticals Corporation $703 45 payments
  3. Horizon Therapeutics plc $296 18 payments
  4. Janssen Biotech, Inc. $279 19 payments
  5. Amgen Inc. $277 16 payments
  6. UCB, Inc. $265 12 payments
  7. Genentech USA, Inc. $217 14 payments
  8. Mallinckrodt Hospital Products Inc. $181 11 payments
  9. E.R. Squibb & Sons, L.L.C. $174 11 payments
  10. Lilly USA, LLC $124 8 payments
  11. Other $475 28 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $4,716 267 payments
  2. Grant $240 1 payment
  3. Education $17 2 payments
Products named General payments · program years 2019–2023
  1. RINVOQ $1,328 54 payments
  2. COSENTYX Immunology $603 38 payments
  3. HUMIRA $586 31 payments
  4. SIMPONI ARIA $293 19 payments
  5. Cimzia $265 12 payments
  6. COSENTYX Dermatology $249 17 payments
  7. Rituxan $217 14 payments
  8. Actemra $202 13 payments
  9. ACTHAR $181 11 payments
  10. STELARA $178 13 payments
  11. Other $2,092 118 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

895

Median for Rheumatology: 1,511

Drug cost

$371,566

Median for Rheumatology: $1,139,948

Branded share of claims

35.8%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 15 $99,447
Cosentyx Sensoready Pen Secukinumab Brand 13 $96,321
Orencia Clickject Abatacept Brand 15 $85,344
Orencia Abatacept Brand 13 $71,723
Hydroxychloroquine Sulfate Generic 173 $5,463
Methotrexate Methotrexate Sodium Brand 230 $4,310
Mycophenolate Mofetil Generic 32 $4,160
Prednisone Generic 212 $1,814
Leflunomide Generic 16 $564
Colchicine Generic 23 $554

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$30,943

Medicare's payments for the services billed

Medicare patients

235

Average age 70

Services billed

681

168 women, 67 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 71%
High blood pressure 67%
Depression 27%
Osteoporosis 25%
Diabetes 24%
Ischemic heart disease 22%
Chronic kidney disease 21%
Cancer 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

270 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record